RxDoctor Payments Data

Carlayne Jackson, MD

Neurology · San Antonio, TXNPI 1083620967

Payments from drug & device makers

$178,483in general payments, 2019–2025

Across 117 payments — averaging $1525.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tanabe Pharma America, Inc.$50K
  • UCB SA$30K
  • Mitsubishi Tanabe Pharma Development America, Inc.$28K
  • Biohaven Pharmaceutical Holding Company Ltd.$27K
  • Catalyst Pharmaceuticals, Inc.$16K
  • CSL Behring$14K
  • plus $15K from 6 others

What the payments were for

  • Consulting fees$38,88650%
  • Speaking & faculty fees$30,21039%
  • Travel & lodging$5,6557%
  • Food & beverage$2,3803%
  • Education$830%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,483 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$23,155
Medicare patients
95
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone181$2,512,612
FirdapseAmifampridine Phosphate31$1,533,844
GammakedImmune Globul G/Gly/Iga Avg 4638$563,659
RelyvrioSod Phenylbutyrat/Taurursodiol22$268,724
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$203,404
RadicavaEdaravone16$203,078
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$134,309
NuedextaDextromethorphan Hbr/Quinidine73$133,320
Riluzole58$9,506
Mycophenolate Mofetil39$8,041
Pyridostigmine Bromide52$4,992
Glycopyrrolate78$4,390
Baclofen36$1,756
Atropine Sulfate13$1,363
Gabapentin30$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$15,872$1,533,84431 claims
CSL BehringPrivigen$14,264$203,40426 claims
Avanir Pharmaceuticals, Inc.Nuedexta$3,949$133,32073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →